List of Equipment Companies in South Korea - 6

Boditech Med Inc. has been developing products for in-vitro diagnostics and diagnostic reagents for the past 20 years by pursuing the value of a company called "Respect for Life"​. In particular, about 60,000 units of ichroma ™ readers are installed and operated world wide, and ichroma™ CRP (C-Reactive Protein) has secured its largest market share in China, showing a unique competitiveness. Boditech Med Inc. is leading the way in exploring new markets through the automation of on-site diagnosed immunodiagnostic devices and the development of new high-sensitive diagnostic reagents. We have built up our reputation successfully by carrying out various national R & D projects based on solid technology, experience, and human resources accumulated over the years. In addition, Boditech Med Inc. is developing a smart production system that integrates digital technology and IT technology to flexibly manage the production scale. All employees of Boditech Med Inc. is making every effort with pride that we are the top leader of BT-IT convergence industry in Korea.

Company goals: to build a consortium of multi-omics tools to help understand and manage bio big data from DNA to Protein in a disease specific manner, and to create a bio big data driven healthcare informatics infrastructure that uses the latest biotechnologies and information technologies to make a seamless and secure integrating platform

MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development. The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments. MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com [ Industry ] Drug Discovery Drug Delivery Biotechnology [ Technology ] MEPS-X series - 3D Microphysiological System platforms MST-X series - Microvortex System, Nanoparticle manufacturing platform MG-X series – Nanomedicine, Biomimetic nanomaterial-based targeted drug delivery platforms